Twist Bioscience stock draws a USD 212 target after Q3 growth
Published on 10/05/2026 at 14:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Twist Bioscience (ISIN US90184D1000) was last at USD 188.67 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, as Guggenheim raised its price target to USD 212 from USD 107 on October 1. The target change puts the spotlight on whether the company can convert rapid synthetic biology growth into profits.
Guggenheim lifts target to USD 212
According to Markets Insider on October 1, 2026, Guggenheim kept a Buy rating and lifted its target from USD 107 to USD 212. The firm adjusted its forecasts ahead of the broader third-quarter earnings season, making the target revision a valuation statement rather than a new company contract.
MarketBeat listed a Moderate Buy consensus from 12 covering firms on September 25, 2026. The breakdown was eight Buy ratings, two Holds and two Sells, while the average 12-month target stood at USD 103.00, according to MarketBeat.
Q3 revenue reaches USD 118.4 million
Twist reported fiscal Q3 2026 revenue of USD 118.4 million, up 23.2 percent from the year-earlier quarter, with gross margin at 52.8 percent. The result marked the company's fourteenth consecutive quarter of growth, while NGS Applications revenue increased 12 percent to USD 61.8 million, as PR Newswire reported on October 1, 2026.
The company also raised fiscal 2026 revenue guidance to USD 456 million to USD 457 million and reiterated its adjusted EBITDA breakeven target for fiscal Q4 2026. That combination gives the stock two separate tests: sustaining revenue expansion and reaching the profitability milestone.
Stock stays near its yearly high
Twist Bioscience had a USD 11.7 billion market capitalization on October 2, 2026. Its USD 23.30 to USD 200.31 52-week range places the last price USD 11.64 below the high, while volume reached 2,082,083 shares.
The market is therefore weighing a clear contrast: fiscal Q3 revenue growth of 23.2 percent and a raised full-year guide against a USD 103.00 average consensus target and continuing losses. For investors, the Q4 adjusted EBITDA milestone is the next measurable test of the growth valuation.
Twist Bioscience stock last at USD 188.67
Twist Bioscience stock was last at USD 188.67 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a daily change of 0.33 percent.
Twist Bioscience stock facts
- Company: Twist Bioscience Corporation
- ISIN: US90184D1000
- Ticker: TWST
- Trading venue: Nasdaq
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 188.67
- Market capitalization: USD 11.7 billion (as of October 2, 2026)
- 52-week range: USD 23.30-200.31 (as of October 2, 2026)
- Sector / Industry: Health Care / Biotechnology
Upcoming dates for Twist Bioscience stock
- November 13, 2026: Fiscal earnings release
